Evidence map›Paper›PMID 33558758›Full record

ArticleNature genetics2021

Comprehensive characterization of protein-protein interactions perturbed by disease mutations.

Feixiong Cheng, Junfei Zhao, Yang Wang, Weiqiang Lu, Zehui Liu, Yadi Zhou, William R Martin, Ruisheng Wang, Jin Huang, Tong Hao and 14 more

Open access · greenAbstract read
In one paragraph

Article in Nature genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 240 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Neo-Cysteine Molecular Glues for Targeting Mutated SMAD4 Protein.Angewandte Chemie (International ed. in English) · 2026
    Article
  14. Article
  15. Article
  16. An interpretable molecular framework for predicting cancer driver missense mutations.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 2 countries.

Feixiong Cheng *Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-1736-2847
Junfei Zhao *Department of Systems Biology, Herbert Irving Comprehensive Center, Columbia University, New York, NY, USA.
Yang Wang *Center for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Weiqiang Lu *Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.ORCID http://orcid.org/0000-0003-1349-6597
Zehui LiuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Yadi ZhouGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
William R MartinGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-0616-0462
Ruisheng WangDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jin HuangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Tong HaoCenter for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7908-3256
Hong YueCenter for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4347-3193
Jing MaCenter for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yuan HouGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Jessica A CastrillonGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Jiansong FangGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Justin D LathiaDepartment of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Ruth A KeriCase Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Felice C LightstoneBiosciences and Biotechnology Division, Physical and Life Sciences Directorate, Lawrence Livermore National Lab, Livermore, CA, USA.ORCID http://orcid.org/0000-0003-1465-426X
Elliott Marshall AntmanDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0808-9199
Raul RabadanDepartment of Systems Biology, Herbert Irving Comprehensive Center, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7946-9255
David E HillCenter for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5192-0921
Charis EngGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-3693-5145
Marc VidalCenter for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Joseph LoscalzoDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jloscalzo@rics.bwh.harvard.edu.ORCID http://orcid.org/0000-0002-1153-8047
Cleveland Clinic Lerner College of Medicine · USHarvard University · USBrigham and Women's Hospital · USColumbia University · USEast China University of Science and Technology · CNCleveland Clinic · USDana-Farber Cancer Institute · USEast China Normal University · CNGuangzhou University of Chinese Medicine · CNLawrence Livermore National Laboratory · USUniversity School · US

Funding

Genomic Analysis of Network Perturbations in Human DiseaseP50HG004233 · NHGRI · DANA-FARBER CANCER INST · PI VIDAL, MARC · 2007 to 2017
$31.6M
Boston Biomedical Innovation CenterU54HL119145 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLAN, DAVID E., LOSCALZO, JOSEPH · 2013 to 2021
$18.8M
The C. elegans Interactome ProjectR01HG001715 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI HILL, DAVID E., ROTH, FREDERICK P · 1998 to 2010
$16.5M
TRANSLATIONAL PHARMACOLOGY COREP50GM107618 · NIGMS · HARVARD MEDICAL SCHOOL · PI MALISZEWSKI, LAURA ELIZABETH · 2014 to 2018
$10.8M
Center for Integrated Approaches to Undiagnosed DiseasesU01HG007690 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2014 to 2022
$10.4M
Endophenotype Network-based Approaches to Prediction and Population-based Validation of In Silico Drug Repurposing for Alzheimer's DiseaseR01AG066707 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng · 2020 to 2026
$4.9M
Resource ProjectU41HG001715 · NHGRI · DANA-FARBER CANCER INST · PI VIDAL, MARC · 2015 to 2017
$4.7M
L-2-Hydroxyglutarate and Metabolic Remodeling in HypoxiaR01HL155107 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Joseph Loscalzo · 2021 to 2026
$4.1M
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertensionR01HL155096 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARON, BRADLEY · 2021 to 2024
$1.6M
An individualized network medicine infrastructure for precision cardio-oncologyR00HL138272 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI CHENG, FEIXIONG · 2018 to 2020
$747k
An individualized network medicine infrastructure for precision cardio-oncologyK99HL138272 · NHLBI · NORTHEASTERN UNIVERSITY · PI CHENG, FEIXIONG · 2017 to 2017
$86k
NHGRI NIH HHS P50 HG004233NHGRI NIH HHS R01 HG001715NHGRI NIH HHS U01 HG007690NHGRI NIH HHS U41 HG001715NHLBI NIH HHS K99 HL138272NHLBI NIH HHS R00 HL138272NHLBI NIH HHS R01 HL155096NHLBI NIH HHS R01 HL155107NHLBI NIH HHS U54 HL119145NIA NIH HHS R01 AG066707NIGMS NIH HHS P50 GM107618
6 · The paper itself

Abstract

Technological and computational advances in genomics and interactomics have made it possible to identify how disease mutations perturb protein-protein interaction (PPI) networks within human cells. Here, we show that disease-associated germline variants are significantly enriched in sequences encoding PPI interfaces compared to variants identified in healthy participants from the projects 1000 Genomes and ExAC. Somatic missense mutations are also significantly enriched in PPI interfaces compared to noninterfaces in 10,861 tumor exomes. We computationally identified 470 putative oncoPPIs in a pan-cancer analysis and demonstrate that oncoPPIs are highly correlated with patient survival and drug resistance/sensitivity. We experimentally validate the network effects of 13 oncoPPIs using a systematic binary interaction assay, and also demonstrate the functional consequences of two of these on tumor cell growth. In summary, this human interactome network framework provides a powerful tool for prioritization of alleles with PPI-perturbing mutations to inform pathobiological mechanism- and genotype-based therapeutic discovery.

Indexed as

MutationArachidonate 5-LipoxygenaseArginineComputational BiologyDiseaseGenome, HumanHistonesHumansNeoplasmsPharmacogenomic TestingProprotein Convertase 9Protein Interaction MapsReceptors, LDLReproducibility of ResultsrhoA GTP-Binding Proteinrho Guanine Nucleotide Dissociation Inhibitor alphaALOX5 protein, humanArachidonate 5-LipoxygenaseArginineARHGDIA protein, humanHistonesLDLR protein, humanPCSK9 protein, humanProprotein Convertase 9Receptors, LDLrhoA GTP-Binding ProteinRHOA protein, humanrho Guanine Nucleotide Dissociation Inhibitor alphaSerine

Identifiers

PMID33558758
PMCPMC8237108
OpenAlexW3128572085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.